ARTICLE
Molecular Diagnostics

Prognostic value of nucleotyping, DNA ploidy and stroma in high-risk stage II colon cancer

Lujing Yang1, Pengju Chen2, Li Zhang1, Lin Wang3, Tingting Sun2, Lixin Zhou1, Zhongwu Li1 and Aiwen Wu2

BACKGROUND: Heterogeneity with respect to recurrence and survival in high-risk stage II colon cancer patients still exists, and further classification is urgently required. This study aimed to ascertain the prognostic value of DNA ploidy, stroma-tumour fraction and nucleotyping in the prognosis of high-risk stage II colon cancer.

METHODS: A total of 188 high-risk stage II colon cancer patients received radical surgery in Peking University Cancer Hospital, from 2009 to 2015. Status of mismatch repair proteins in tumours was analysed using immunohistochemistry. DNA ploidy, stroma-tumour fraction and nucleotyping were estimated by automated digital imaging systems.

RESULTS: Nucleotyping and DNA ploidy were significant prognostic factors, while stroma-tumour fraction were not significantly prognostic in the univariate analysis. In the multivariable model, the dominant contributory factor of disease-free survival was chromatin heterogeneous vs. chromatin homogeneous [HR 3.309 (95% CI: 1.668–6.564), P = 0.001].

CONCLUSIONS: Our study indicates that nucleotyping is an independent prognostic factor in high-risk stage II colon cancer. Therefore, it may help subdivide patients into different subgroups and give them different strategies for follow-up and treatment in the future.

British Journal of Cancer (2020) 123:973–981; https://doi.org/10.1038/s41416-020-0974-8

BACKGROUND

According to the recent statistical estimate of cancer prevalence in China, colorectal cancer (CRC) was the third most frequently diagnosed cancer in both males and females in 2011. Although some patients diagnosed with stage II colorectal cancer will recur and die of the disease, the need to administer postoperative adjuvant chemotherapy is disputed. At present, many experts do not recommend adjuvant chemotherapy to patients without one of the high-risk factors, which include lymph nodes sampling less than 12, poorly differentiated tumour, vascular or perineural invasion, pathological T4 stage tumours and clinical presentation with intestinal occlusion or perforation. Including one of these factors can be defined as high-risk stage II colon cancer. Although it is possible to categorise stage II colon cancer patients into low-risk group and high-risk group, previous studies have shown that there is heterogeneity within high-risk stage II colon cancer patients in terms of its prognosis. The present study investigates the use of additional biomarkers to further stratify patients with high-risk stage II colon cancer, providing a basis for individualised treatment in the future.

In recent years, several studies shown that chromosomal instability (CIN) is the driving force underlying cellular DNA aneuploidy in tumours. Errors in chromosome separation during cell division can result in an uneven distribution of chromosomes between the two daughter cells. This and replication stress may contribute to CIN. DNA aneuploidy or tetraploidy is an accepted marker of CIN that has been shown to be associated with poor prognosis in CRC. In addition, other studies have shown that CIN-associated cancers exhibit enhanced invasiveness, which may increase the likelihood of metastasis of CRC.

Single nucleotide polymorphisms, chromosome structure and number changes, and genome arrangement may lead to genetic and epigenetic alterations in tumour cells, which can be detected by analysing chromatin texture in the nucleus. Chromatin texture analysis provides information on the spatial arrangement of pixel grayscale values in digital images of cell nuclei stained specifically for DNA. The nucleotyping method that we selected attempts to detect heterogeneous chromatin organisation through automatic texture analysis of digitised images of nuclei. A previous study has demonstrated that nucleotyping is a pan-cancer prognostic factor.

The stroma-tumour fraction, described as the ratio of area occupied by carcinoma cells to total occupied by stromal cells and carcinoma cells in primary tumours, can be evaluated in sections stained with haematoxylin and eosin (H&E). Previous studies have shown that stroma-tumour fraction is an independent prognostic parameter in CRC and other solid epithelial tumours. In most of the studies, there is a 0.5 threshold for subdividing patients into low-stroma and high-stroma groups. Patients with high stroma...
were observed to have worse prognosis than patients with low stroma.21,23

Microsatellite instability can also cause CRC.25 The repair of microsatellite regions in DNA is controlled by mismatch repair (MMR) genes that encode various proteins, including MLH1, MSH2, MSH6 and PMS2. Deficiency of certain proteins may cause microsatellite instability, although patients with mismatch repair deficient (dMMR) CRC had improved disease-free survival (DFS) relative to patients with mismatch repair proficient status (pMMR).26

Currently, there are only few studies focused on high-risk stage II colon cancer patients. Therefore, the purpose of this study was to investigate the effect of DNA ploidy, stroma-tumour fraction and nucleotyping on the prognosis of high-risk stage II colon cancer.

METHODS

Patient population

We retrospectively analysed all surgically resected high-risk stage II colon cancer samples in the Department of Pathology, Peking University Cancer Hospital, from 2009 to 2015. This study used formalin-fixed and paraffin-embedded (FFPE) samples of 188 recorded cases of high-risk stage II colon cancer without neo-adjuvant chemoradiotherapy that were available for analyses.

Immunohistochemistry

Immunohistochemistry (IHC) was performed using PowerVision Two-Step Histostaining Reagent (ImmuVision Technologies, Brisbane, CA). Briefly, FFPE blocks were cut into 4-μm sections, dewaxed in xylene, rehydrated by decreasing alcohol gradient and washed twice in phosphate-buffered saline (PBS). Antigen retrieval was performed on tissue samples with EDTA buffer (pH 9.0; Santa Cruz Biochemistry, Dallas, TX) for 3 min in a pressure cooker. Endogenous peroxidase activity was blocked by incubation in 3% H2O2 solution at 25 °C for 10 min. After blocking with 5% normal goat serum, sections were incubated with mouse anti-MLH1 monoclonal antibody (Clone ES05, Shanghai Genetech, Shanghai, China), anti-PMS2 monoclonal antibody (Clone EP51, Shanghai Genetech, Shanghai, China), anti-MSH2 monoclonal antibody (Clone RED2, Shanghai Genetech, Shanghai, China) and anti-MSH6 monoclonal antibody (EP49, Shanghai Genetech, Shanghai, China) at 4 °C overnight. This was followed by incubation with anti-mouse Immunoglobulin (IgG) horseradish peroxidase conjugate (Beijing Zhongshan Golden Bridge Biotechnology, Beijing, China) at 25 °C for 30 min. Antibody binding was visualised using a 3,3'-diaminobenzidine kit (Beijing Zhongshan Golden Bridge Biotechnology, Beijing, China) according to the manufacturer’s instructions. For general negative controls, the primary antibodies were replaced by phosphate-buffered saline. All sections were examined microscopically and evaluated by two independent pathologists (Zhiwu Li and Li Zhang) who were unaware of the clinical information pertaining to the subjects. IHC staining was negative when all tumour cells showed loss of nuclear staining. Tumours that yielded negative staining results for at least one of the four MMR proteins, were classified as dMMR tumours, and all others were classified as pMMR tumours.

Tumour sampling

For nucleotyping, DNA ploidy and stroma analyses, the pathologist selected one tumour block deemed representative from each patient and annotated the whole epithelial tumour region. Hence, no systematic selection was carried out. The DNA ploidy, stroma and nucleotyping analysis processes were carried out in Ningbo Meishan FTZ M&M Clinical Lab Co., Ltd.

DNA image cytometry

FFPE tissue sections were cut at 5 μm and stained with H&E for defining the tumour region. One or two 50-μm sections, containing more than 90% representative tumour tissue, were cut from the tumour region marked on FFPE tissue blocks. The sections were deparaffinised in xylene, rehydrated through decreasing alcohol gradient, and washed twice in PBS. The sections were incubated at 37 °C at 83 × g for 1 h with 0.5 mg/mL protease VIII to disaggregate the cells. Cold PBS was added and the tubes were placed in an ice bath to stop enzymatic digestion. The cell suspension was filtered through a 60-μm mesh nylon filter and centrifuged at 415 × g (Sigma 3K-1) for 10 min. After discarding the supernatant, the pellet was resuspended in PBS. A volume of 100 μL of the solution was cyto spun at 250 × g for 5 min to prepare a monolayer of nuclei on a slide. The monolayer preparations were air-dried and fixed overnight in 4% formaldehyde before stained using Feulgen’s method.27

Measurement of DNA content

The Feulgen-stained nuclei were measured with DNA Ploidy Working Station (Room 4, Kent, UK), as previous report.27 Briefly, an image of each nucleus was captured by a high-resolution digital scanner (Aperio AT2, Leica, Germany), and images were automatically grouped into different galleries for tumour nuclei, reference nuclei and discarded nuclei. DNA ploidy histograms were created from the integrated optical density (IOD) of the nuclei using PWS Classifier (Room 4, Kent, UK). The reference nuclei were used as an internal diploid control, and DNA ploidy histograms were classified into four groups: diploid, aneuploid, tetraploid and polyploid according to a previous report.28 Aneuploid, tetraploid and polyploid samples were grouped as non-diploid in this study.

Nuclear texture analysis

Nucleotyping was automatically assessed as proposed in a previous study.20 Each tumour sample was independently classified using PWS Classifier and the same set of images of tumour nuclei that the DNA ploidy histogram was based on. Chromatin organisation was quantified by computing the entropy of pixel grey levels in a subregion of a nucleus. The frequency in which each pair of entropy and centre grey level occur throughout a nucleus was stored in a two-way table, known as the grey level entropy matrix (GLEM). GLEMs stratified on nuclear area and subregion size were concatenated to form a four-dimensional expansion of the GLEM called GLEM4D. In a previous study,20 an adaptive machine learning algorithm was applied to quantify the association between each element of the GLEM4D and the outcome of the patient. In the current study, these pretrained weights were directly applied to predict the outcome of a patient on the basis of the GLEM4D representation of its tumour. This was done by multiplying each element of the patient’s GLEM4D with the corresponding weight computed in the previous study,20 thereafter adding the products. The result was a continuous value termed the chromatin value, which describes the overall amount of chromatin disorder in a given patient sample.20 According to the threshold of 0.044, the tumours were classified into chromatin homogeneous (CHO, ≥ 0.044) or chromatin heterogeneous (CHE, < 0.044).

Stroma-tumour fraction

Stroma-tumour fraction was determined on H&E stained histological sections. H&E stained sections were routinely estimated under 10 × 10 lens microscope to select the sections rich in tumour (tumour tissue > 50%, necrotic tissue < 10%). The stroma-tumour fraction was measured by Stroma Analyzer (Room 4, Kent, UK), as was described by Danielsen et al.29 Briefly, the whole slides images of H&E stained sections were scanned with an Aperio AT2 digital slide scanner at ×40 (Leica, Germany), giving a resolution of 0.23 μm per pixel. Images with a resolution of 1.82 μm per pixel were used for image processing. A senior pathologist (Li Zhang) marked the tumour areas on the scanned images by using the
software tool (Stroma analyzer, Room 4, Kent, UK). The stroma fraction in the selected tumour region was automatically calculated by the software (Stroma analyzer, Room 4, Kent, UK). Tumours with stroma fraction less than or equal to 0.50 were labelled low stroma, while those with stroma fraction greater than 0.50 were labelled high stroma.

Follow-up
Patients were followed at 6 months intervals for the first 2 years after treatment, and annually thereafter. Evaluations consisted of physical examination, a complete blood count, serum carcino-embryonic antigen levels and blood chemical analysis. Proctoscopy, CT imaging of the abdomen and pelvis, and chest radiography were also routinely performed every 6–12 months after treatment.

Statistical analysis
The endpoints were overall survival (OS) and DFS. OS was defined as the time between the date of initial surgery and date of death for any reason or the date of the last follow-up. DFS was defined as the time from the date of initial surgery to the date of death for any cause or the first local recurrence or metastasis. IBM SPSS Statistics for Macintosh, Version 20.0 (IBM Corp, Armonk, NY) software was used for all analyses. Kaplan–Meier survival curves with log-rank estimates were used to depict time-to-event parameters. Univariate and multivariate cox proportional hazards models were established to obtain hazard ratios with 95% confidence interval for parameters. Correlation analysis were performed using Spearman correlation coefficients. >0 indicates a positive correlation and coefficient <0 indicates a negative correlation. The statistical significance level was set at 0.05. We established a total of six multivariable models, a correction for multiple comparisons was performed. Thus, a two-sided P-value of less than 0.008 was considered statistically significant for each multivariable model.

RESULTS
Patient demography
Totally, 188 consecutive cases including 121 male and 67 female patients were involved in this study. The median age of patients was 62.2 years, the majority of patients was pT3 (pT3 vs. pT4, 66.5% vs. 33.5%) and 56.9% of all patients were treated with chemotherapy after surgery (Capecitabine alone, Oxaliplatin, leucovorin and 5-FU, or Oxaliplatin and Capecitabine). Other patients’ characteristic and distribution of relevant parameters are listed in Table 1.

At the end of follow-up, 161 patients were still alive and 35 patients had a recurrence or metastasis. Median OS and median DFS were 68 months (25–75% quartiles: 55–92 months) and 66 months (25–75% quartiles: 52–91 months), respectively.

A positive correlation between pathological T-stage and stroma-tumour fraction was observed in our cohort (coefficient = 0.153, P = 0.037), which meant that the higher the pathological T-stage, the more the tumour stroma. A negative correlation between diploid and poorly differentiated was observed (P = −0.215, P = 0.005). A positive correlation between DNA ploidy and nucleotyping was observed (P = 0.743, P < 0.001). Except for one diploid tumour, chromatin homogeneous (CHE) was almost exclusively found in non-diploid tumours. A negative correlation between diploid and pMMR was observed (coefficient = −0.237, P = 0.001). (Supplementary Tables 1 and 3).

Univariate prognostic factors
Of all 188 cases, our mean follow-up was 71 months. Analysis of DFS and OS in high-risk stage II colon cancer are shown in Table 2. DNA ploidy and nucleotyping were found to be significant in univariate analysis of DFS (P = 0.006 and P < 0.001, respectively) (Fig. 1). Patients with pT4 tumours had an inferior DFS compared to patients with pT3 tumours (P = 0.024). Stroma-tumour fraction was not a significant prognostic factor for DFS. In our cohort, 83.7% and 71.4% was the recurrence and metastasis rate of the stroma-low and stroma-high group, respectively, and the power calculation was 0.184. No significant prognostic impact was observed for dMMR, utilisation of adjuvant chemotherapy and other risk factors for high-risk stage II colon cancer in univariate analyses.

The combinations of nucleotyping and stroma; DNA ploidy and nucleotyping and DNA ploidy were analysed.

According to the length of DFS, the combination of nucleotyping and stroma was divided into three groups, and it was found that chromatin homogeneous (CHO) and low-stroma patients had the highest 5-year DFS [89.2% (95% CI: 83.8–94.6%)] of the three groups (low risk), while the CHO and high-stroma or CHE and low-

| Table 1. Distribution of relevant parameters. |
|---------------------------------------------|
| Variables                                   | n   | %  |
| Age, years                                  |     |    |
| ≤63                                         | 90  | 47.9 |
| >63                                         | 98  | 52.1 |
| Gender                                      |     |    |
| Male                                        | 121 | 64.4 |
| Female                                      | 67  | 35.6 |
| Lymph nodes sampling                        |     |    |
| ≥12                                         | 152 | 80.9 |
| <12                                         | 36  | 19.1 |
| Histological grade                          |     |    |
| Well differentiated                         | 7   | 3.7 |
| Moderately differentiated                   | 123 | 65.4 |
| Poorly differentiated                       | 55  | 29.3 |
| Mucinous differentiated                     | 3   | 1.6 |
| Vascular or perineural invasion             |     |    |
| Yes                                         | 55  | 29.3 |
| No                                          | 133 | 70.7 |
| pT stage                                    |     |    |
| pT3                                         | 125 | 66.5 |
| pT4                                         | 63  | 33.5 |
| Intestinal occlusion or perforation         |     |    |
| Yes                                         | 37  | 19.7 |
| No                                          | 151 | 80.3 |
| Mismatch repair status                      |     |    |
| pMMR                                        | 124 | 66.0 |
| dMMR                                        | 64  | 34.0 |
| Adjuvant chemotherapy                       |     |    |
| No                                          | 81  | 43.1 |
| Yes                                         | 107 | 56.9 |
| DNA ploidy                                  |     |    |
| Diploid                                     | 88  | 46.8 |
| Non-diploid                                 | 100 | 53.2 |
| Stroma                                      |     |    |
| Low stroma                                  | 153 | 81.4 |
| High stroma                                 | 35  | 18.6 |
| Nucleotyping                                |     |    |
| Chromatin homogeneous                       | 152 | 80.9 |
| Chromatin heterogeneous                     | 36  | 19.1 |

pMMR mismatch repair proficient, dMMR mismatch repair deficient.
Table 2. Univariate analysis on overall survival and disease-free survival of the prognostic factors in high-risk stage II patients.

| Variable                                      | n  | OS, % | HR (95% CI) | P-value | DFS, % | HR (95% CI) | P-value |
|-----------------------------------------------|----|-------|-------------|---------|--------|-------------|---------|
| **Age**                                       |    |       |             |         |        |             |         |
| ≤63                                           | 90 | 80.0  | 1           | 75.6    | 1      |             | 0.034   |
| >63                                           | 98 | 90.8  | 0.431 (0.194–0.960) | 86.7 | 0.520 (0.262–1032) | 0.057   |
| **Lymph nodes sampling**                      |    |       |             |         |        |             |         |
| ≥12                                           | 152| 85.5  | 1           | 80.9    | 0.431 (0.194–0.960) | 86.7 | 0.520 (0.262–1032) | 0.814   |
| <12                                           | 36 | 86.1  | 1.032 (0.390–2.727) | 83.3 | 0.900 (0.373–2.169) | 0.520   |
| **Histological grade**                        |    |       |             |         |        |             |         |
| Well differentiated                            | 7  | 71.4  | 1           | 71.4    | 1      |             | 0.690   |
| Moderately differentiated                     | 123| 85.4  | 0.548 (0.127–2.375) | 78.9 | 0.782 (0.185–3.310) | 0.548   |
| Poorly differentiated                          | 55 | 87.3  | 0.464 (0.096–2.248) | 87.3 | 0.446 (0.092–2.156) | 0.464   |
| Mucinous                                      | 3  | 100.0 | –           | 100.0   | –      |             | 0.433   |
| **Vascular or perineural invasion**           |    |       |             |         |        |             |         |
| Yes                                           | 55 | 87.3  | 1           | 80.0    | 1      |             | 0.920   |
| No                                            | 133| 85.0  | 0.956 (0.402–2.276) | 82.0 | 0.745 (0.363–1.528) | 0.420   |
| **pTstage**                                   |    |       |             |         |        |             |         |
| pT3                                           | 125| 90.4  | 1           | 87.2    | 1      |             | 0.053   |
| pT4                                           | 63 | 76.2  | 2.111 (0.974–4.576) | 79.8 | 2.111 (0.974–4.576) | 0.024   |
| **Intestinal occlusion or perforation**       |    |       |             |         |        |             |         |
| Yes                                           | 37 | 81.1  | 1           | 78.4    | 1      |             | 0.349   |
| No                                            | 151| 86.8  | 0.665 (0.281–1.573) | 82.1 | 0.798 (0.362–1.757) | 0.574   |
| **Mismatch repair status**                    |    |       |             |         |        |             |         |
| pMMR                                          | 124| 84.7  | 1           | 80.6    | 1      |             | 0.420   |
| dMMR                                          | 64 | 87.5  | 0.611 (0.165–1.410) | 82.8 | 0.704 (0.342–1.447) | 0.444   |
| **Adjuvant chemotherapy**                     |    |       |             |         |        |             |         |
| No                                            | 81 | 81.5  | 1           | 77.8    | 1      |             | 0.122   |
| Yes                                           | 107| 88.8  | 0.552 (0.258–1.184) | 84.1 | 0.675 (0.347–1.313) | 0.340   |
| **DNA ploidy**                                |    |       |             |         |        |             |         |
| Diploid                                       | 88 | 90.9  | 1           | 89.8    | 1      |             | 0.053   |
| Non-diploid                                   | 100| 81.0  | 2.216 (0.969–5.068) | 74.0 | 2.770 (1.296–5.918) | 0.006   |
| **Stroma**                                    |    |       |             |         |        |             |         |
| Low stroma                                    | 153| 86.9  | 1           | 83.7    | 1      |             | 0.345   |
| High stroma                                   | 35 | 80.0  | 1.510 (0.638–3.573) | 71.4 | 1.782 (0.855–3.711) | 0.118   |
| **Nucleotyping**                              |    |       |             |         |        |             |         |
| Chromatin homogeneous                         | 152| 89.5  | 1           | 86.2    | 1      |             | 0.001   |
| Chromatin heterogeneous                       | 36 | 69.4  | 3.518 (1.618–7.646) | 61.1 | 3.302 (1.671–6.526) | <0.001  |
| DNA ploidy and stroma                         | 0.135| 0.135| 3.518 (1.618–7.646) | 61.1 | 3.302 (1.671–6.526) | 0.011   |
| **DNA ploidy and stroma**                    |    |       |             |         |        |             |         |
| Diploid and low stroma                        | 77 | 90.9  | 1           | 89.6    | 1      |             | 0.155   |
| Diploid and high stroma or non-diploid and low stroma | 87 | 83.9 | 1.802 (0.727–4.466) | 79.3 | 2.081 (0.905–4.788) | 0.001   |
| Non-diploid and high stroma                   | 24 | 75.0  | 2.926 (0.982–8.712) | 62.5 | 4.036 (1.556–10.472) | 0.033   |
| **Nucleotyping and stroma**                   |    |       |             |         |        |             |         |
| Chromatin homogeneous and low-stroma          | 130| 90.0  | 1           | 86.9    | 1      |             | 0.033   |
| Chromatin homogeneous and high-stroma or Chromatin heterogeneous and low-stroma | 45 | 77.8 | 2.345 (1.028–5.349) | 73.3 | 2.148 (1.026–4.499) | 0.002   |
| Chromatin heterogeneous and high-stroma       | 13 | 69.2  | 3.575 (1.159–11.033) | 53.8 | 4.161 (1.635–10.595) | <0.001  |
| **DNA ploidy and nucleotyping**               |    |       |             |         |        |             |         |
| Diploid and chromatin homogeneous             | 87 | 90.8  | 1           | 89.7    | 1      |             | 0.002   |
| Diploid and chromatin heterogeneous or non-diploid and chromatin homogeneous | 66 | 87.9 | 1.330 (0.499–3.545) | 81.8 | 1.845 (0.777–4.382) | <0.001  |
| Non-diploid and chromatin heterogeneous       | 35 | 68.6  | 4.140 (1.653–10.370) | 60.0 | 4.632 (1.995–10.752) | 0.001   |

pMMR mismatch repair proficient, dMMR mismatch repair deficient, OS overall survival, DFS disease-free survival.
Prognostic value of nucleotyping, DNA ploidy and stroma in high-risk...  
L Yang et al.

![Kaplan–Meier plots illustrating DFS for patients with tumours that were chromatin homogeneous (CHO) and chromatin heterogeneous (CHE) among patients with high-risk stage II colon cancer.](image)

**Fig. 1 DFS in nucleotyping.** Kaplan–Meier plots illustrating DFS for patients with tumours that were chromatin homogeneous (CHO) and chromatin heterogeneous (CHE) among patients with high-risk stage II colon cancer.

Stroma patients had intermediate 5-year DFS (82.2% (95% CI: 70.6–93.8%)), referred to as medium-risk group. The HR was 2.148 (95% CI: 1.026–4.499). The CHE and high-stroma patients had the lowest 5-year DFS (61.5% (95% CI: 30.9–92.1%)), which is referred to as the high-risk group. The HR was 4.161 (95% CI: 1.635–10.595).

The combination of nucleotyping and stroma was statistically significant on DFS ($P = 0.003$) (Fig. 2).

Similarly, as in a previous study,$^{29}$ the combination of DNA ploidy and stroma was divided into three groups, which were respectively called low-risk, medium-risk and high-risk groups according to DFS. Low-stroma and diploid tumours represented patient groups with high 5-year DFS (89.6% (95% CI: 82.7–96.6%)), which we defined as low-risk group, while high-stroma and diploid tumours together with low-stroma and non-diploid tumours represented intermediate-risk group. Compared to the low-risk group, this group had decreased 5-year DFS (78.8% (95% CI: 70.8–86.8%)), which was defined as the medium-risk group. The HR was 2.081 (95% CI: 0.905–4.657). High-stroma and non-diploid tumours represented high-risk group. The HR was 4.161 (95% CI: 1.635–10.595).

The combination of nucleotyping and stroma was statistically significant for DFS ($P = 0.003$) (Fig. 2).

In multivariable analyses of prognostic factors for DFS

In a multivariable model, nucleotyping, DNA ploidy, stroma, the combination of nucleotyping and stroma, the combination of DNA ploidy and stroma and the combination of nucleotyping and DNA ploidy were used as independent variables, respectively. Age and pathological T-stage were adjusted to establish multivariable analysis models.

After a correction for multiple comparisons, we found that nucleotyping and the combination of nucleotyping and DNA ploidy can be used as effective factors for DFS of high-risk stage II colon cancer.

In multivariable analysis model with the combination of nucleotyping and DNA ploidy as the independent variable, the dominant contributory factors on DFS was the combination of nucleotyping and DNA ploidy (HR 4.382 (95% CI: 1.909–10.319), $P = 0.001$) for the high-risk group vs. low-risk group. In multivariable analysis model with nucleotyping as the independent variable, the dominant contributory factor for DFS was nucleotyping (HR 3.309 (95% CI: 1.668–6.564), $P = 0.001$) for the CHE vs. CHO (Table 3).

**DISCUSSION**

Although tumour-node-metastasis is currently the best prognostic factor for CRC, it still cannot properly risk-stratify all patients, especially for stage II colon cancer patients.$^5$ Whether patients with high-risk stage II colon cancer can benefit from adjuvant therapy is still controversial, suggesting tumour biological heterogeneity in these patients.$^3$ A previous study has shown that chemotherapy improves survival in stage II colorectal cancer, although the absolute improvements are only 3.6%.$^3$ Therefore, we sought to identify more accurate prognostic factors to further classify patients with high-risk stage II colon cancer. Our study demonstrated that nucleotyping was the dominant prognostic factor in high-risk patients with stage II colon cancer, whether in...
univariate or multivariable analyses. In high-risk stage II colon cancer patients, the DFS of CHE patients was significantly shorter than that of CHO patients. For CHO patients, our research showed that their 5-year DFS rate was high (88.8%). These results lead to the conclusion that nucleotyping is an independent prognostic factor in high-risk stage II colon cancer. Based on these evidences, it is necessary to further stratify those patients for the purpose of personalised treatment in the future.

Tumour progression is accompanied by genomic and epigenetic changes that make tumours progressively aggressive. These changes alter the nuclei in multiple ways: including the size of the nucleus, the density of DNA, and the structure of chromatin. Nucleotyping is a quantitative analysis of the degree of nuclear disorder of tumours by integrating the three types of changes in the tumour cell nuclei through artificial intelligence, in order to ascertain the degree of malignancy of tumour cells in different patients. A pan-cancer study has shown that nucleotyping can be a prognostic factor for many tumours, including stage I or II colorectal cancer. Cancer-specific survival rates in patients with CHE are lower than that of patients with CHO. Our research produced similar results, since we found that nucleotyping could predict the prognosis of patients with high-risk stage II colon cancer.

To our knowledge, this study was the first external and independently performed evaluation of nucleotyping by a completely different team than the original Kleppe A team. The multivariable analysis model displayed with nucleotyping as an independent variable could predict recurrence and metastasis in high-risk stage II colon cancer patients. Therefore, we believe nucleotyping can further stratify existing high-risk stage II colon cancer patients, providing a more accurate basis for guiding clinical personalised medicine.

Consistent with previous studies, pathological T-stage had an impact on the prognosis of patients in our study. Previous studies have shown that in multivariable analysis, increased age and the absence of adjuvant chemotherapy are risk factors for stage II colon cancer. Different from these studies, our study showed that adjuvant chemotherapy had no significant effect on survival or recurrence and metastasis of cancer in patients, while the overall survival rate of older patients was higher than that of younger patients. This may be attribute to the fact that our study subjects were high-risk stage II colon cancer patients, with the median age was younger than that of study mentioned above. This study was consistent with another study that found that DNA ploidy was negatively correlated with dMMR status. This may be attributed to methylation of many promoters being associated with tumour diploidy and dMMR. Nucleotyping markers can reflect the degree of chromosomal disorder, including information about the chromatin structure, which can explain the correlation between nucleotyping and DNA ploidy.

Sheltzer et al. reported that aneuploid genomic instability may contribute to aggressive growth of advanced malignant tumours with complex karyotypes. Although the mechanisms by which non-diploid tumours affect the prognosis of patients has not been well elucidated, previous studies have shown that non-diploid tumours promote the development of tumours, and whole genome doubling promotes resistance to a broad spectrum of chemotherapeutic drugs and can also lead to genomic instability. Non-diploid tumour has been proven a statistically significant predictor of poor prognosis of many cancers, including CRC. The results of our univariate analysis suggested that, similar to previous results, there was no significant difference in overall survival between diploid and non-diploid patients, this might attribute to a small sample size in our study. However, the DFS of diploid patients was significantly longer than that of non-diploid patients.

Previous studies have confirmed that patients with stroma-high stage II colorectal cancer have a poor prognosis. One study showed that patients with stroma-high tumours in CRC had worse OS compared to patients with stroma-low tumours. Alternatively, in analysis of DFS, no significant differences were observed between patients with stroma-high and stroma-low tumours. Our results showed that the prognosis of the high-stroma group was worse than that of the low-stroma group, regardless of whether OS or DFS was used as the study endpoint. However, the difference was not statistically significant, contrary to previous studies, but this might be due to the small sample size and low power calculation. Expanding larger the sample size is required to accurately analyse the prognostic value of stroma. For stroma analysis, as was described by Danielsen et al., we
studied tumour-enriched areas and evaluate all tumour areas on whole scanned images, rather than studied the areas with the deepest part of the tumour and to use a microscope with an area the size of a ×10 objective to select tumour areas. Besides, some patients did not receive adjuvant therapy because they were too old or for financial reason, this may affect the prognosis. All of the above reasons may lead to different results from previous studies.

The present study was limited by single-centre design with small sample size, sampling error and short follow-up time, criteria for assessment, and different adjuvant chemotherapy regiments used. Fewer cases of recurrence, metastasis and death may reduce the quality of statistical analysis. Future research will be directed at following up and expanding the sample size to further determine the reliability of the results herein.

ACKNOWLEDGEMENTS
We thank all investigators and patients for participating to this study and Lijun Mao and Fei Wang for their technical support.

AUTHOR CONTRIBUTIONS
Z.W.L. and A.W.W. conceived and designed the experiments. L.J.Y., P.J.C., L.Z., L.W., T.T.S. and L.X.Z. performed the experiments. L.J.Y. and P.J.C. analysed the data. L.X.Z. contributed the materials/analysis tools for the study. L.J.Y., P.J.C. and T.T.S. updated the follow-up data for all cases. L.J.Y. wrote the manuscript. Z.W.L. revised the manuscript. All authors have read and approved the final manuscript.

ADDITIONAL INFORMATION
Ethics approval and consent to participate This study was performed in accordance with legal requirements after approval by the Ethics Committee of Peking University Cancer Hospital. Informed consent was obtained from all individual participants included in the study. This study was performed in accordance with the Declaration of Helsinki.

Data availability All data not included in this published article are available upon reasonable request. Supplementary information is available on the British Journal of Cancer’s website.

Competing interests The authors declare no competing interests.

Funding information This study was supported by the Beijing Municipal Science and Technology Commission NOVA program (No. 2010 B033), the Beijing Municipal
Prognostic value of nucleotyping, DNA ploidy and stroma in high-risk...
L Yang et al.

Science and Technology Commission Capital Characteristic Clinical Application Research (No. Z141107002514077). Capital’s Funds for Health Improvement and Research 2018-2-1022 and the National Nature Science Foundation of China (No. 81773214).

Supplementary information is available for this paper at https://doi.org/10.1038/s41416-020-0974-z.

References

1. Chen, W., Zheng, R., Baade, P. D., Zhang, S., Zeng, H., Bray, F. et al. Cancer statistics in China, 2015. CA Cancer J. Clin. 65, 115–132 (2016).

2. Schrag, D., Rias-Shiman, S., Saltz, L., Bach, P. B. & Begg, C. B. Adjuvant chemotherapy for Medicare beneficiaries with stage II colon cancer. J. Clin. Oncol. 20, 3999–4005 (2002).

3. Weiss, J. M., Schumacher, J., Allen, G. O., Neuman, H., Lange, E. O., Loconte, N. K. et al. Adjuvant chemotherapy for stage II right-sided and left-sided colon cancer: analysis of SEER-medicare data. Ann. Surg. Oncol. 21, 1781–1791 (2014).

4. Jemal, A., Ward, R. C., Murray, T., Samuels, A., Mathers, D. W. et al. Cancer statistics, 2004. CA Cancer J. Clin. 54, 8–29 (2004).

5. Benson, A. B. 3rd, Venook, A. P., Cederquist, L., Chan, E., Chen, Y. J., Cooper, H. S. et al. Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. J. Natl Compr. Canc. Netw. 15, 370–397 (2017).

6. Schmoll, H. J., Van Cutsem, E., Bach, T., Bardou, M., Beoga, B., Calvo-Asensio, I., et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer, a personalized approach to clinical decision making. Ann. Oncol. 23, 2479–2516 (2012).

7. Merkle, S., Wein, A., Gunther, K., Papadopoulos, T., Hohenberger, W. & Hermanek, P. High-risk groups of patients with Stage II colon cancer. Cancer 92, 1435–1443 (2001).

8. Babcock, B. D., Aljehani, M. A., Jab, B., Choi, A. H., Morgan, J. W., Selleck, M. J. et al. High-risk stage II colon cancer: not all risks are created equal. Ann. Surg. Oncol. 25, 1980–1985 (2018).

9. Davoli, T., Xu, A. W., Mengwasser, K. E., Sack, L. M., Yoon, J. C., Park, P. J. et al. Cumulative haplinsufficiency and triposensitivity drive aneuploidy patterns and shape the cancer genome. Cell 165, 948–962 (2016).

10. Reish, O., Regev, M., Kanesky, A., Girafi, S. & Masheivich, M. Sporadic aneuploidy in PMA-stimulated lymphocytes of trisomies 21, 18, and 13. Cytogenet. Genome Res. 133, 184–189 (2011).

11. Burrell, R. A., McClelland, S. E., Endesfelder, D., Groth, P., Weller, M. C., Shahk, N. et al. Replication stress links structural and numerical cancer chromosomal instability. Nature 494, 492–496 (2013).

12. Eykelenboom, J. K., Harte, E. C., Canavan, L., Pastor-Peidro, A., Calvo-Asensio, I., et al. The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage. Cell. Oncol. 29, 387–398 (2007).

13. Wang, K., Ma, W., Wang, J., Yu, L., Zhang, X., Wang, Z. et al. Tumor-stroma ratio is an independent predictor for survival in esophageal squamous cell carcinoma. J. Thorac. Oncol. 7, 1457–1461 (2012).

14. Zhang, X. L., Jiang, C., Zhang, Z. X., Liu, F., Zhang, F. & Cheng, Y. F. The tumor-stroma ratio is an independent predictor for survival in nasopharyngeal cancer. Oncol. Res. Treat. 37, 480–484 (2014).

15. Chen, Y., Zhang, L., Liu, W. & Liu, X. Prognostic significance of the tumor-stroma ratio in epithelial ovarian. Cancer Biomed. Res. Int. 2015, 589301 (2015).

16. Boland, C. R. & Goel, A. Microsatellite instability in colorectal cancer. Gastroenterology 138, 2073–2087 (2010).

17. Popat, S., Hubner, R. & Houlston, R. S. Systematic review of microsatellite instability and colorectal cancer prognosis. J. Clin. Oncol. 23, 609–618 (2005).

18. Liefers, G. J. & Quesney, F. L. DNA measurement of overlapping cell nuclei in thick tissue sections. Ann. Clin. Pathol. 14, 41–49 (1997).

19. Pradhan, M., Abeler, V. M., Danielsen, H. E., Sandstad, B., Trope, C. G., Kristensen, G. B. et al. Prognostic importance of DNA ploidy and DNA index in stage I and II endometrial adenocarcinoma of the endometrium. Ann. Oncol. 23, 1178–1184 (2012).

20. Danielsen, H. E., Hveem, T. S., Domingo, E., Pradhan, M., Kaje, A., Syvertsen, R. A. et al. Prognostic markers for colorectal cancer: estimating ploidy and stroma. Ann. Oncol. 26, 616–623 (2018).

21. Meyer, B. M., Cosby, R., Quereshi, F. & Jonker, D. Adjuvant systemic chemotherapy for stages II and III colon cancer after complete resection: a clinical practice guideline. Curr. Oncol. 23, 418–424 (2016).

22. Gray, R., Barnwell, J., McConkey, C., Hills, R. K., Williams, N. S. & Kerr, D. J. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 370, 2020–2029 (2007).

23. McFarland, C. D., Korolev, K. S., Kryukov, G. V., Sunyaev, S. R. & Mirny, L. A. Impact of deleterious passenger mutations on cancer progression. Proc. Natl Acad. Sci. USA 110, 2910–2915 (2013).

24. Podlaha, O., Riesler, M., De, S. & Michor, F. Evolution of the cancer genome. Trends Genet. 28, 155–163 (2012).

25. Park, J. H., Richards, C. H., McMillan, D. C., Horgan, P. G. & Roxburgh, C. S. The relationship between tumour stroma percentage, the tumour microenvironment and survival in patients with primary operable colorectal cancer. Ann. Oncol. 25, 644–651 (2014).

26. Scheer, R., Baidooshvili, A., Zoidze, S., Elfinkin, M. A. G., Berkel, A. E. M., Klaase, J. M. et al. Tumor-stroma ratio as prognostic factor for survival in rectal adenoarcinoma: a retrospective cohort study. World J. Gastrointest. Oncol. 9, 466–474 (2017).

27. Enkisen, A. C., Sorensen, F. B., Lindebjerg, J. Hager, H., dePont Christensen, R., Kjaer-Frifeldt, S. et al. The prognostic value of tumour stroma ratio and tumour budding in stage II colon cancer. A nationwide population-based study. Int. J. Colorectal Dis. 33, 1115–1124 (2018).

28. Carvalho, B., Pinto, M., Cirmes, L., Oliveira, C., Machado, J. C., Suriano, G. et al. Concurrent hypermetllylation of gene promoters is associated with a MSI-H phenotype and diploidy in gastric carcinomas. Eur. J. Cancer 39, 1222–1227 (2003).

29. Sheltzer, J. M., Ko, J. H., Replogle, J. M., Habibe Burgos, N. C., Chung, E. S., Meehl, C. M. et al. Single-chromosome gains commonly function as tumor suppressors. Cancer Cell 31, 240–255 (2017).

30. Fujiwara, T., Bandi, M., Nitta, M., Ivanova, E. V., Bronson, R. T. & Pellman, D. Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells. Nature 437, 1043–1047 (2005).

31. Kuznetsova, A. Y., Seget, K., Moeller, G. K., de Pagter, M. S., de Roos, J. A., Durrbaum, M. et al. Chromosomal instability, tolerance of mitotic errors and multidrug resistance are promoted by tetraploidization in human cells. Cell cycle 14, 2810–2820 (2015).

32. Danielsen, H. E., Pradhan, M. & Novelli, M. Revisiting tumour aneuploidy—the place of ploidy assessment in the molecular era. Nat. Rev. Clin. Oncol. 13, 291–304 (2016).

33. Vogelaar, F. J., van Pelt, G. W., van Leeuwen, A. M., Willems, J. M., Tollenaar, R. A., Liefers, G. J. et al. Are disseminated tumour cells in bone marrow and tumor-stroma ratio clinically applicable for patients undergoing surgical resection of primary colorectal cancer? The Leiden MRD study. Cell Oncol. 39, 537–544 (2016).
43. Sandberg, T. P., Oosting, J., van Pelt, G. W., Mesker, W. E., Tollenaar, R. & Morreau, H. Molecular profiling of colorectal tumors stratified by the histological tumor-stroma ratio - Increased expression of galectin-1 in tumors with high stromal content. *Oncotarget* 9, 31502–31515 (2018).
44. van Pelt, G. W., Sandberg, T. P., Morreau, H., Gelderblom, H., van Krieken, J., Tollenaar, R. et al. The tumour-stroma ratio in colon cancer: the biological role and its prognostic impact. *Histopathology* 73, 197–206 (2018).
45. Geessink, O. G. F., Baidoshvili, A., Klaase, J. M., Ehteshami Bejnordi, B., Litjens, G. J. S., van Pelt, G. W. et al. Computer aided quantification of intratumoral stroma yields an independent prognosticator in rectal cancer. *Cell Oncol.* 42, 331–341 (2019).
46. Sandberg, T. P., Sweere, I., van Pelt, G. W., Putter, H., Vermeulen, L., Kuppen, P. J. et al. Prognostic value of low CDX2 expression in colorectal cancers with a high stromal content—a short report. *Cell Oncol.* 42, 397–403 (2019).